Literature DB >> 9777836

Abnormal colonic fermentation in irritable bowel syndrome.

T S King1, M Elia, J O Hunter.   

Abstract

BACKGROUND: The cause of irritable bowel syndrome (IBS) is unknown. It may follow gastroenteritis and be associated with an abnormal gut flora and with food intolerance. Our study was designed to assess whether these factors were associated with colonic malfermentation.
METHODS: We carried out a crossover controlled trial of a standard diet and an exclusion diet matched for macronutrients in six female IBS patients and six female controls. During the final 72 h on each diet, faecal excretion of fat, nitrogen, starch, and non-starch polysaccharide NSP was measured, and total excretion of hydrogen and methane collected over 24 h in a purpose-built 1.4 m3 whole-body calorimeter. Breath hydrogen and methane excretion were then measured for 3 h after 20 g oral lactulose.
FINDINGS: The maximum rate of gas excretion was significantly greater in patients than in controls (2.4 mL/min IQR 1.7-2.6 vs 0.6, 0.4-1.1). Although total gas production in patients was not greater than in controls (median 527 mL/24 h IQR 387-660 vs 412, 234-507), hydrogen production was higher (332, 318-478 vs 162, 126-217, p=0.009). In patients, the exclusion diet reduced symptoms and produced a fall in maximum gas excretion (0.5 mL/min IQR 0.3-0.7). After lactulose, breath hydrogen was greater on the standard than on the exclusion diet.
INTERPRETATION: Colonic-gas production, particularly of hydrogen, is greater in patients with IBS than in controls, and both symptoms and gas production are reduced by an exclusion diet. This reduction may be associated with alterations in the activity of hydrogen-consuming bacteria. Fermentation may be an important factor in the pathogenesis of IBS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777836     DOI: 10.1016/s0140-6736(98)02146-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  88 in total

1.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

2.  Intestinal Gas.

Authors:  Rebecca N. Fink; Anthony J. Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2001-08

3.  Detection of cellulolytic bacteria from the human colon.

Authors:  J Kopecný; J Hajer; J Mrázek
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

4.  Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

5.  A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial.

Authors:  Yu-jing Fan; Shu-jie Chen; Ying-cong Yu; Jian-min Si; Bin Liu
Journal:  J Zhejiang Univ Sci B       Date:  2006-12       Impact factor: 3.066

Review 6.  Expert commentary--bloating, distension, and the irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  MedGenMed       Date:  2005-01-10

7.  Bloating and intestinal gas.

Authors:  Michael P Jones
Journal:  Curr Treat Options Gastroenterol       Date:  2005-08

8.  Irritable bowel syndrome: bacteria and inflammation--clinical relevance now.

Authors:  Robin C Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

9.  Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice.

Authors:  E F Verdú; P Bercik; M Verma-Gandhu; X-X Huang; P Blennerhassett; W Jackson; Y Mao; L Wang; F Rochat; S M Collins
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

Review 10.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.